allergan is so much better. growing so much faster. but valeant decided allergan was vulnerable. think it's a shame, david pyott had the best growth. >> and put up numbers. way back when this started we questioned valeant's business model over and over. they've had strong numbers as well. roll up with low tax rate, eviscerating r&d. first letter written by pierson as opposed to ackman who continued to have the barrage. >> are they at odds, buddies? >> they're not buddies. ackman saying we've got to do this, bid more, higher. >> not going to break the glass either. >> they're not clinking glasses. they say valeant's letter a tactic to distract investors from allergan's outstanding third quarter results. it does not disclose a mix of conversation. it goes to great less to defend its stock price. there you have it, the latest back and forth. >> listen to kindler, pyott. it's funny that best performing -- the best of the fastest growth of the major pharmas was allergan and that's being picked on not pfizer, where they know how to buy back stock. what's pfizer's real strength? knowing

the ceo of allergan himself authorized allergan to release information about valeant company for theurpose of attempting to manipulate the stock price down. it was a conscious strategy by the senior most of allergan's management team and also thinking the new developments only increase the likelihood of the deal happening. this new information came to light over the weekend when a judge forced allergan to give documents to per shing square and value i can't as part of a discovery process. mr. akman saying he think this is new information only increases the likelihood of this valiant and allergan deal actually taking place. so we have reached out to allergan for comment. if we get one we'll share it with you. but it's already been a contentious fight. taking more of that turn this hour. airlines have been volatile. gaining ground today after selling off on ebola fiercears. >> gordon, what is the answer for the airlines at this point? >> i think they go o about. they are profession men and women and will do their job. they are going to rely on the government and cdc do their job and pr

it feels like what they're saying is if allergan would quit criticizing our stock our stock would soar to new highs and that would make the stock portion of the hostile take over much more valuable. let's take a look at the chairman and ceo of allergan and get to the bottom of the situation. >> thank you. >> all right now, you're one of the longest running guests on our show. how is the company able is make so much money now versus say a year and a half ago before valiant got involved? >> luckily for us if there was a time to be dealing with this it's a time when you have a huge momentum in sales growth and this last quarter you gave the number 17% dollar growth. it was the very best quarter in all of our 64 years as a company. >> now, some of this is botox but it's the logical that really shocks them. where is that major growth coming from? it's always been good but now it seems great. >> yeah, there too we have great momentum. this past quarter about 14% worldwide growth. that's in the market growing about 11%. so again we're exceeding overall market growth driven by multiple product

>> we do own allergan stock. we are a passive shareholder. we're happy to be aligned with pershing square. ultimately what we want them to do is to sell their company nor highest price possible. >> do you like the valeant deal. >> if it gets the highest price fantastic. if activist can do more they should do a attraction with them. i think the key is ultimately to present a transaction to shareholders to a vote that maximizes value. lower cost through leverage and -- that i don't think allergan can achieve on its own. >> do you think valeant is going to raise the offer. >> i think ultimate allergan will raise the bid. i don't think valeant is going to win. there is a natural fight for those who show first. hopefully what they will have done is convince the aler began board that they need to do something. they can't keep their head in the sand. 35% of the shareholders called for a special meeting. change will occur. they need to embrace that and deliver tchange that creates th highest value. . we want to make money through allergan shares gett

i guess we're going to cover allergan at some point. >> we are.uld have done a bit more on it yesterday. never too late. we'll have more on that today. of course, you're right, the overall theme of strength to grow that we kid about sometimes is in full force along with activism. we're seeing it yet again today on emc, which we'll also talk a bit about. >> opening bell. s&p at the top of your screen. at the big board, eagle point credit card celebrating its ipo today. bunch of names to get to. we covered yum. that's probably worth checking once again as we begin to look to some of the first big names to report earnings. 87 cents, did miss by a penny. revenue was short. china comps, of course, we knew that was going to be the story. the estimate was for down 13. we got down 14. they lower their guidance for the year looking at 6% to 10%. >> and the quotation there on china, same-store sales growth from yum management, while sales are rebounding, they continue to be negative. >> what's interesting is the stock has opened in positive territory. it ma

you want to broaden your portfolio, allergan we think of as botox. no.'s an opthamological play. >> general electric, of all people, out with their own attempt at a viral ad. jeff goldblum in a mock commercial. >> now you can get successful guy lighting at normal guy prices. the ge link light bulb, less for over 22 years and only costs $14.97. that's 66 cents a year. i spend that on moist towelettes every 13 seconds. that's too much. >> that runs about 90 seconds. >> i don't want to put light bulbs in my will. i don't want to have to say, i've got a tortoise that is going to live to 110. i don't need light bulbs that will live there. >> does he have gopro on his shell yet? >> i'm worried about the tortoise's head. three years it turns out it's a woman, a female? you put pressure on the shell, it hurts them. >> the shell is very sensitive. >> yes. there is a dachshund video i watched last night. there is a lot of stuff being done with gopro. a lot of it. >> did you see the frog worm video? >> i haven't seen that one. you say i watch everything. feeble att

this new bid game as allergan posted results that topped analysts expectations. shares of novavax surged today on news that trials for its ebola vaccine are advancing. the drug developer is already doing a nonhuman study of the vaccine and the ceo says testing will progress rapidly. >> we expect to be able to make doses in the tens of thousands in this clinical trial by december and by the end of the first quarter we'll be able to manufacture at our by o tech company be able to manufacture in the millions of doses per month. >> the stock popped 13% on that news to $5.80. a setback for another company. the food and drug administration is asking for information on the biotech's application for its new ms drug. this means that the filing for the treatment will now be delayed into mid2015. shares there down 32% today alone closing at $15.91. >>> strong quarterly earnings from citizens financial. they were up more than 30% from last year. it also declared a 10 cent quarterly dividend it will pay to shareholders in november. despite that shares were down to 22.85. micr

it it ain't no pepsi or allergan.doesn't look like it will end any time soon, but we'll know when we get to the right levels and we'll tell you. we'll get through this together and i'm not telling you to abandon ship. "mad money" tonight, find out what allergan and pepsico have in common and why it has me steamed and why j.p. morgan and target have all one thing in common. hacking attacks that have left your data compromised and tonight i'm highlighting a new security player that could be up to the task to protecting you online. zoe's kitchen, can it continue to cook? i have exclusive insight you won't want to miss. stay with cramer. >> don't miss a second of "mad money," pfollow @jimcramer on twitter. send jim an email to madmoney@cnbc.com or give us a call at 1-800-743-cnbc. miss something? head to madmoney.cnbc.com. so i can reach ally bank 24/7, but there are no branches? 24/7 it's just i'm a little reluctant to try new things. what's wrong with trying new things? feel that in your muscles? yeah... i do... try a n

. >>> allergan, the maker of botox says it is under-valued, it has been reported that allergan raised the bid. shares closed at 187.55 apiece. amazon, the 800-pound guerilla wanting to open the first brick and mortar store. opening in manhattan across from the empire straight building. the store would also reportedly function as a mini warehouse with limited inventory for same-day delivery right within new york city. the stock lost more than 2% closing at $315 and change. semantec the latest company to split up. after of the closing bell, the tech firm known best for the anti-virus software will trade two companies. one focusing on software seales they finished the regular session down at 2.5% to close at 23.44. mixed quarterly results after the closing bell from family dollar, the discount chain reporting better than expected revenues. a slight lift on earnings per share. the company didn't provide forward guidance because of the pending acquisition by the rival, dollar tree. family dollar up 4 cents a share, closing at $70.75. >>> a warning for many of the millions of americans with

allergan refused to comment on those claims. out now again. >> yes. >> and you were they are lying about what? >> i think they're -- i guess at the beginning of this they said the third quart ser going to be the true test of valeant. and we will have annualized bausch and lomb. the wheels are falling off the bus. i think today's earnings shows bausch and lomb continues to grow. the rest of the company, you know, 19% including bausch and lomb. they made a lot of allegations that have proved not to be true. >> there's a bernstein report -- i don't know if you saw this -- where doctors indicated that they would switch from valeant if you took over allergan to other providers. do you believe that? and what do you think it is about valeant that has the medical community on edge? >> i've spent the last three or four weekends with doctors. the leaders in the united states and canada. and for the very purpose of talking to them about valeant and our model. and i think all this misinformation that allergan has put out has affected the do

david pyatte, allergan were all bad ceos.t consumer products, best tech, highest growing, best quality of earnings. i don't know what the world is coming to. it's extraordinary. >> the ten year hit 2.27. rick santelli would know better than i. he joins us from chicago. rick. >> yesterday, 2:00 eastern, the market changed in a new york minute. let's look at the charts. let's start at the beginning of the curve. let's look at at two-year for a one-year chart. it's at the lowest yield since mid august. you can see how it's developing. the further down the curve you go, the more developed it gets. look at a one-year of fives and there is the lowest yield since about august, as well. you can see how that's moving lower. as a matter of fact, the five-year was the real big mover yesterday. the yield curve actually took a break from long term flattened rates and started to steepen. now it gets interesting. look at the ten year. now back up at 2.31. if you open that chart up, let's start the chart may 2013 to get some view. hovering a

the move is to keep allergan from striking a rival deal. shares up each. the close at $190.50, valeant finished at $125.90. >>> and at&t is paying to consumer refunds to settle allegations that it added bogus third party charges to cell phone bills. daily horoscopes or trivia never requested. enforcement action for this so-called cramming is the largest in the history of the federal communications commission. at&t shares up, though, nearly 1% to $33.15. >>> citi group is gearing up to spin off the subprime lending unit. one main financial, which makes personal loans to consumers with less than pristine credit is preparing a $50 million initial stock offering. citi group tried but failed to sell the business before and now says one name no longer fits with the strategy. >>> switching to politics with under four weeks to go before the midterm elections, and the focus now is on kansas and what some considered to be the most important race in the country, one that could determine whether republicans will take control of the u.s. senate. john harwood joins us w

i continue to think that you want to own allergan. there's just a lot of ways to win allergan. do what it wants. there are forces in play that make it so allergan is worth more both on an earnings per share basis and a takeover basis. >> all right. let's get to dominic chu, see what's moving on the floor. >> all right. so i'm in that crowd that you're showing is just on the right-hand side of your screen. next to post five. more on that in a second. what we have right now are markets that are lower. the dow is down about 45 points. and the concern right now is really about global growth. there really isn't that much robust growth to be concerned about if you're a bear. so if you take a look at the global markets, the dow is down, the s&p is down, but european markets are down as well. you're seeing concerns there as well. the euro also at a two-year low right now. as you see what's happening with the euro, if you wanted that european vacation, you can get it on the discount, on sale right now for what the euro is trading at. and that's all because you take a look at the europea

>> the answer from allergan's ceo might surprise you.cramer's exclusive coming up at the top of the hour. meantime, we have your first move tomorrow when we come right back. stay tuned. twhat do i do?. you need to catch the 4:10 huh? the equipment tracking system will get you to the loading dock. ♪ there should be a truck leaving now. i got it. now jump off the bridge. what? in 3...2...1... are you kidding me? go. right on time. right now, over 20,000 trains are running reliably. we call that predictable. thrillingly predictable. so right now if you get the 15 gig plan, we'll double the data and make it 30 gigs for the same price. 30 gigs? wow - that's a lot. you don't have to do that for me. oh, that's ok... (interrupting) seriously, i wouldn't want you to get in trouble... it's the same plan for everyone. families...businesses...whoever. riiiiight. (yelling) no celebrity treatment here! (yelling) there really isn't any celebrity treatment. just a normal guy, getting a great deal. we're just saying it loudly for some reason. now get 30

we are all exhausted. >> let's talk about allergan in particular.is not an acquirer at that point in time. , maybe looking for some kind of defensive play. >> yes, they have been talked about. now it is trying to buy them. they're looking to make themselves potentially too big for value to buy. there was talk that activist might buy them at one point. they were rumored to have some other deals. everyone is trying to figure out, how do they live, how do they avoid getting bogged, but it is just -- >> all of this has been good for pharma stocks. all of this deal, talk, and action making the stocks. thank you so much, good to talk to you. that is it for "on the markets," street smart is next. >> welcome, everyone, to the most important hour of the session with 60 minutes to the close. i'm trish regan. stocks rebounding for the fourth day partly due to speculation that the ecb is buying bonds. we will get the numbers and hear from marissa mayer after the bell. and i'm joined by former hp ceo carly fear reena -- carly fear reena. -- carly fiorin

look at the results of merck, allergan and amgen as well as buffalo wild wings. >>> and the failed ecbstress tests exposed a 25 capital shortfall among the bank that is failed. the biggest capital shortfall was 2.1 billion euros. as you can see that's up 17.5%. by far the biggest faller from these results for bmps. even with a rise in 2.76% for commerz bank. and soc gen is down while major banks fared well. one to mention is lloyds bank that narrowly passed the test today down 2.2%. now annetta is back to join us from frankfurt with more on the stress tests. >> reporter: thank you very much. well, the big hope by the ecb is that the stress tests are now for capital lending, but there are some concerns that this is not going to help the economy as it is weak. so i had a chance yesterday to ask the vice president of the ecb whether in the case that the unconventional measures to partake and don't bear fruit, they would also consider buying corporate bonds. take a listen. >> that was not discussed in the government council, so it is not on the table. there were all these rumors that in th

at the same time allergan is much opposed and have tried various ways to do it. including litigation. and a as well raising questions about a stance taken yesterday by valeant to potentially raise their roughly $179 per share offer to 200. note worthy too that michael pearson the ceo of valeant was walking in this morning as well. he'll be at the hearing in orange county as well. and back to you. >> a know a lot of people in your space are watching that. >>> tesla, late yesterday the "wall street journal" reporting rough numbers for the auto maker. reporting sales of the model s through september fell 20% year over year. didn't take too long for ceo elon musk to dispute that. quote the article is incorrect. september was a record high and up 65% year over year in north america. tesla doesn't report monthly sales. it only reports on a quarterly basis. the next time being early november. kevin o'leary, what do you make of the fact that ceo's can now just take to twitter to dispute anything they see in the press? >> i like the transparence but my advice is to follow

>> i think we have to talk about allergan. would be up much less if it weren'ter to valeant. look at earnings for allergan. i'm not quick to say this is all valeant. we'll talk about brazil. i listened to your guest who thinks brazil's not done. it's the worst market in the world. maybe take a look at it pick among the rubble. petrobras not bad a company. >> what are we going to decide who is the markets? is it oil, ebola, the fed, earnings? earnings? >> i think it's going to be earnings. the calendar's amazing. look merck up from 53, can it hold on that number? i think people are sanguine about it. we do have oils, exxon and chevron at the end of the week. goldman sachs does a downgrade of the oils. do you throw in the towel at 80 or declare victory at 100? second-rate analysts commentary. deutsche bank upgrades alcoa. it's a field day of fun, because most analysts have really not distinguished themselves during this period. >> jim, we've got to go. i look at you, someone told me that high-def was not my friend. were we worri

. >>> it's time to weigh back to valiant allergan. it was largely going to be stock what i believe to be the case. that raise never came even though it was reported to be imminent. there is not going to be a raise before the meeting december 17th. monday, valeant will report earnings. they are going to be very good. very strong numbers. strong cash flow. a real reaffirmation of the business model there in terms of what they will show with the new products. the belief previously was and the strategy was you get a higher stock price from that and momentum going into it. after it, you raise your bid. their stock price is not high enough to get enough traction from raising at all. in the allergan camp, they believe they are going to go into this meeting and still be able to win. they are going to tell shareholders, by the way, if we don't get a majority of the board, we'll drop our bid. no surprise there, of course. my expectation still is they will raise the bid prior to the meeting. perhaps they raise it after iss. those meetings will t

who is coming in, he's a big shareholder in both allergan and shire. he's not apparently urging them to make a tie up, which would obviously mean that is valeant/allergan deal may not happen. and this is something, which is why we've seen shire's share price recovery slightly this morning. we will wait and see what the next move is here. it doesn't look like the trend for contoll addition is over yet. >> it's a long way from consensus of getting something pushed through on this topic. are companies moving too soon with the deal? >> there has been a lot of speculation that abbvie was overly cautious in this particularly when there had been a move even since the deal with a announced on the 22nd. there had been a deal where they said this is still going through, this is still attractive despite inversion. and i think it will mean that deals for which tax inversion is the main focus probably won't go through. but there is still some room for consolidation. there's fear, there's a lot of recovery companies, there's a lot of cash in balance sheets. we could

valiant and bill ackman are reportedly planning to boost their bid for allergan by 15% a share.uld value the botoxmaker at more than $56 billion. allergan would reportedly entertain an offer of $200 a share. vallant's bid would be $191 a share. taking a look at those stocks and how they're trading, allergan up about 4% in trading. >>> in other news, tim geithner will be back on the stand today in the lawsuit against aig abailout. on tuesday, geithner, president of the new york fed in 2008 said he believed allowing aig to fail would have been catastrophic. geithner believes that the bailout wiped out shareholders, although he acknowledged that -- in the past. it's expected former fed chair ben bernanke won't testify until thursday 37. >>> coming up, can jcpenney's ceo convince shareholders it's ahead of the track? stay tuned. and that became our passion. to always build something better, airplanes that fly cleaner and farther on less fuel. that redefine comfort and connect the world like never before. after all, you can't turn dreams into airplanes unless your passion for innovat

it's allergan and then maybe bristol-meyers is the innovators.s time to throw out that management team. >> you're being sarcastic. >> greed is good. >> he would certainly say that. as we close in, december 18 not that far away from that allergan special meeting. the court case in california not concluded whether they will be successful, unlikely, in validating mr. ackman's 9.7% stake. at the meeting itself, i would point out it is going to be majority of outstanding shares. not the easiest hurdle. >> i hate to bring up the fundamentals of allergan. the o pfrn tfpthomological are . and botox. there is a lot of off-label use of botox that. company is doing really well. time warner cable being acquired by our parent company. regulators have yet to fully weigh in here. that's why i hesitated to say is definitely happening. however, of course, the expectation is it will happen. time warner cable lost 184,000 video subscribers in the third quarter. that was better than last year when they had the feud with cbs and lost 306,000, but it's not good. it's

bill ackman plans to raise their takeover bid for allergan. it will make their new offer in december, close to the shareholder meeting with some that's where some directors may be removed. allergan has characterized these previous bids as grossly inadequate. americans are living longer than ever before. edit be born in 2012 expect to live almost 78 years. expectancy for women is little more than 81 years. for men, slightly less than 77. cancer and heart disease remains the big killers. alcoa kicks off third-quarter earnings and season after the bell. mike mckee says if you're looking at earnings per share, you are looking at the wrong thing. is the convention that has developed. did company x meet forecasts or not? it depends on whether their stock will go up or down. that's not how people who know what they are doing say this should be done. matt company. earnings by nature don't tell you anything about what's going to happen. stock markets are supposed to look six months ahead. they look three months back. it's not a good indicator of what y

>> i like it, and i like allergan. they're all in situations that i think will likely do better for shareholders than work, it's fine with me. how about boris in new york. >> caller: thank you for your show, the combination is entertaining. >> thank you. >> caller: my question is about lazar financial services. >> if you like this at 3.5% i think it's a buy. why do i have to wait in the whole complexion is going down and i don't want to be too eager. let's go to dave in california, dave? >> caller: booyah. i want to know about avnr. >> we have to look at this thing, it spiked big on a new win, and we have to go back over and make a decision. i cannot opine on it right now, taking one more call, i'm not making fun of people who stutter, and i know there are people champions of that cause, i don't want to get in the way of that. let's go to jay in texas. >> caller: booyah, jim. mine is chart industries. >> nay missed the quarter, they missed the quarter, what happens when you keep missing quarters your stock gets cut. le

allergan under attack. if you spend that much money on r&d, i want to see new drugs. merck, there is nothing to write home in that one either. you go over celgene. just creating drugs by the day. i want companies that grow. >> while we are at it, and we'll get to this, sanofi shares are going to be down. >> fierce pharma, here is the headline, don't fire me. david, don't fire me. don't fire me. >> they are citing competition in the diabetes market. he potentially was attempting to sell them mature drugs which they are no longer doing and seemed to have run afoul. >> diabetes. is this "don't fire me" the same conversation rex ryan is having right now with woody johnson? >> i don't know. probably. >> don't you think this is embarrassing? i like him. he's been on the show. don't fire me approach has this, maybe i shouldn't buy that stock. >> when you're asked not to be fired. >> the geno smith of diabetes. meg terrell is at the amgen investor meeting. >> just now ceo bob bradway was presenting to analysts and investors. the company announced restructuring in the second q

carefusion, becton dickinson and allergan. there is an interesting theme developing among a lot of these stocks. that is something i know you can appreciate. the consumer theme. check out shares of coca-cola or altria. altria first. you can see both stocks up since the 19th. one of the best performers outside the ones that have done deals has been nike. the athletic apparel and foot wear maker has gotten off to a good start here in this quarter. specifically, just since those market peaks. even though we've seen this rollover, this 4.5% drop in the s&p 500, nike, altria, coca-cola, a lot of these consumer names are weathering the storm better than some of the other stocks in the s&p. back to you. >> that dividend doesn't hurt. >> low rates. >> the dow had its best day of the year wednesday. its worst day yesterday. all three indices erasing early gains. back in negative territory. vix back above 20. joining us now "new york times" columnist jim stuart. what do you make of this week? >> i've been saying do you want it sooner or

from banana buyouts, valiant pharmaceuticals announces in a letter to allergan it is enkriegs its bider share. >> thank you. amazon workers in germany on streak again. the union there is in a long-running battle, a wage battle with the online retailer. workers-at-least four logistics centers will be off the job through wednesday's late shift. amazon shares are down 27% this year, trading up a buck at 288. it's rare a ceo and insider becomes a straight investor. courtney reagan has a man that led some of the best known brands in the industry, now all he does is pick winners, plus, we want to hear from you. will you vis eight mall before christmas? courtney, over to you. >> thank you so much. i am here with glen, the former ceo of urban outfitters. now he is the ceo and chairman of a private equity firm to invest in consumer companies, thank you so much for being with us today, glen. you give an interesting talk in there. let's start out with an opening ceremony. it's your big investment that we are aware of. that's the company partnered with intel, how did you know that that was a winn

we are also relaxing to the re-eight -- latest on allergan, the latest on his activism role and how heg activist approaches to shareholders and companies here in europe. the market is taking a pounding and he will be great on what is happening globally. the macro picture and those meetings in washington, we will try to keep it tight and keep it real and i want to ask him what it was like to ring the gong? they have a good gong here. it comes from indonesia with a lot of history here. the question, is there a future? >> another question, why amsterdam? i know there was a rumor he wanted to list in london but why europe? >> we will be pressing him on that, his point here is that you have great access to capital markets here, and you can get a lot of difficult exposure. we will try to press him on that , why not london question mark why not frankfurt? why not paris? he can make the case that the oldest shareholders are here, an interesting story, 1608, the first activist investors that were called "crybaby shareholders." is he a crybaby or an activist investor. call that man a crybaby. in

. -- you were saying allergan. under pressure from third point to break itself up.ys today is not best interests of shareholders. an investor day coming up. aggressive -- she met with the ceo over the summer and having a constructive activist area. >> it is proof that sometimes these days as an activist all you have to do is show up. >> auteur. we will be back in just a moment. ♪ >> live from bloomberg headquarters in new york, this is "market makers," with erik schatzker and stephanie ruhle. >> nothing to tweet home about. investors are hammering twitter today. they want to know why its growth rate is stuck in slow gear. >> hiidden treasure. madison square garden might split up to online value in its basketball and hockey teams. to realize value and its basketball and hockey teams. >> welcome to the second hour of "market makers." today, a guest anchor all over locket -- oliver luckett. >> consumers have not been this confident in seven years. dence board is that the highest level since before the recession. reasons.a number of consumers continue to go to t-mobile.

and allergan, another deal that's not been resolved.ormous mega deals in the pharma space are actually proving very, very difficult to pull off, and it will have to see whether anyone can, in fact, get one done. >> let's talk tech. qualcomm making a bid for a radio, c.s.r. it's not a massive deal, it's a pretty big deesm a surprise, though. i think everybody has been caught by this one. >> a bit of a surprise to see qualcomm come in, absolutely. we were not expecting that. there were negotiations between c.s.r. and microchip, which is nother u.s. company. qualcomm came in with a big price, blowing everyone out of the water. this is all about where the semiconductor space is going. we've actually seen a few deals. infineon made a recently sizable acquisition in the u.s. several weeks ago. everyone wants to catch the next big wave in semiconductors. the consensus is that that is the so-called internet of things, which is a somewhat horrible expression, but basically it means that everything is going to be wired, everything will be hooked

billion and pershing square hoped the third time's a charm, planning yet another bid for allergan, the maker of botox. this time, increase could be varied at about $15 per share. bill ackman first approach the company back in april. float his retirement system is set to cut pimco investments po box was at the state will significantly reduce the $2 billion pension they have invested with the firm and also withdraw more than $1 billion for the for a one-stop program offer to workers. go to the twitter question of the day. >> we just heard from michael holland how he is playing to selloff. our twitter question of the day, what is your investment strategy as stock selloff? tweet off. going to the triple leverage cash fund. three other percent cash. >> that is time strategy. we will be right back on "bloomberg surveillance." ♪ >> good morning, "bloomberg surveillance." international monetary fund, look for that at 10:00 this morning on "market makers." the imf out with a stunning pre-report over the last number of days on global slowdowns. the official report at 9:00 a.m. this morning. look

securing it going with meetings with allergan. >> they have not been willing to meet with us.here are serious governance issues there. i think ultimately we will get the right answer. shareholders have called for a special meeting and we are leading the charge and hopefully that will take place in december and i think the new board will likely be installed. >> there is legal insurgency whether you can vote your 9.7% share. consequence remote i think that will be settled by the courts. well before december 18. from terms of a new offer you, will you have a new offer before the december meeting? >> it is something we will announce when we announce it area and . >> that is not a manner like to reveal a whole lot before he is forced to. he knows his way around the media and in terms of what that come to me maybe where he will put some of that $6 billion in cash. version ofinvestor an answer dam striptease from bill ackman. someone that knows how to build a little suspense before he moves in for the kill. >> if he suffers from lack of confidence, he rarely, if ever, reveals it. ask

talks with allergan cooled. i reported first on activist having some interest.e'll see how that progresses. >> excellent reporting. >> thank you. >>> when we come back, cramer's mad dash as we count down to the opening bell. we'll look at the premarket. all the things we haven't talked about yet. the dollar on another tear. gold has gone negative for the year. and that jobs number at 248,000. . you are going for "usa today." >> i want to talk first. you have to take a deep breath before you talk about this topic ebola. it is so easy to scare people and that is not what i want to do. that's why i refer to someone else. ebola upsets exxon drilling plan is the "usa today" story. this is not about nigeria. what i'm pointing out here is oil today is down again. it did bounce off $89. it's coming down again. this is amazing. why? there are 3 million barrels a day that come out of nigeria. nigeria is not that far from this area. if you can imagine a situation where 3 million were to come offline because of ebola, you would think something would move the price of oil up

again, a reuters report that actavis may make a plan for a takeover possibly within a week and that allergan would be open to a sale of a price tale above dollar 200 according to sources familiar, a reuters report. we'll watch the shares, spiking up toward session highs up by 2% on the session. back over to you guys. >> dom, thank you. but again, trading $187. reminds me of what time warner did rebuffing and saying we can get the shares or only consider offers above $100 and a lot of companies, dom, takeover targets in the market and feel the confidence with the way the stock market behaving or a recovery despite the concerns listing. they feel like they can say, no, here's the price. >> we are talking about a market that's let's not forget just a stone's throw away from record highs. talking about the takeover offers, there might be a sense that you can get deals done at price premiums, especially if there's interest on both sides to get a deal done. we are not -- we haven't forgotten about the fact that valiant pharmaceuticals and other dynamics of their deal, a lot of different factors co

. >> the whole dispute with allergan and valiant are they throwing so much money at research over the long run doesn't return anything to them, enough to them, right? >> yeah. but again, i think in this case, the criticism is valid and companies are punting. they don't know what it is they are supposed to be doing with money and they have got a lot of cash, but with a pfizer, they spend a lot of money on r & d. the problem is they are salesmen, spend twice as much on r&d, wouldn't be able to cover the problems of their sales force, right? the companies don't have a long-term strat jury means i wouldn't buy those shares even though they are. >> dom has more on this one now. dom? >> not so much more but just color because to put it in perspective, pfizer shares are currently trading call it about $29 a share. if you take 11 billion divided by 29 per share, the quick and dirty math, talking over 379 million shares of stock that they are going to be buying back over the course of this program. that's pretty decent chunk, guys. >> somebody made the comment the other day regarding buying, e

rioters reports they plan to approach allergan about a takeover for a second time.d informal talk earlier this year. >> entrepreneurship is not just for young tech savvies, dropouts, and hoodies, but they can run with ideas. endeavor is a global organization that identifies mentors and coinvests in entrepreneurs in 30 different countries. the ceo is here, with a new book "crazy is a compliment, the power of zigging when everyone else zags," and she determined "the next list," and thank you so much for joining us this morning. >> great to be here. well, you know, my voice on the next list was to say it can't just be the boys in hoodies and startups. not only a are third women and half over 40, but third a nonfounders. this relates to why i wrote "crazy is a compliment," and after working with a thousand entrepreneurs, i got people from in the companies, i need to get ahead, i don't trust my job. help me think like an entreprene entrepreneur, whether i start of my own thing or just take control of my job. >> i love how you say it's not just for techties. drop out of c